洛匹那韦/利托那韦和阿比多尔治疗新型冠状病毒肺炎的疗效

中华传染病杂志 Pub Date : 2020-02-15 DOI:10.3760/CMA.J.ISSN.1000-6680.2020.02.006

Jun Chen, Y. Ling, X. Xi, Ping Liu, Feng Li, Tao Li, Zhiyin Shang, Mei Wang, Yinzhong Shen, Hongzhou Lu

{"title":"洛匹那韦/利托那韦和阿比多尔治疗新型冠状病毒肺炎的疗效","authors":"Jun Chen, Y. Ling, X. Xi, Ping Liu, Feng Li, Tao Li, Zhiyin Shang, Mei Wang, Yinzhong Shen, Hongzhou Lu","doi":"10.3760/CMA.J.ISSN.1000-6680.2020.02.006","DOIUrl":null,"url":null,"abstract":"Objective \nTo evaluate the efficacies of lopinavir/ritonavir and abidol in the treatment of novel covonavirus pneumonia (NCP). \n \n \nMethods \nThe clinical data of 134 patients with NCP receiving treatment at Shanghai Public Health Clinical Center during January 20 to February 6, 2020 were retrospectively collected. All the patients received interferon-α2b spray and symptomatic supportive treatment, and 52 cases received oral lopinavir/ritonavir treatment, 34 cases received oral abidol treatment, the remaining 48 cases did not take any antiviral drugs. The efficacies of the three groups were compared, and Chi-square test was used for statistical analysis. \n \n \nResults \nThe 134 patients included 69 males (51.5%) and 65 females (48.5%), aged 35 to 62 years with the average of 48 years. The median time to temperature normalization in patients receiving abidol or lopinavir/ritonavir treatment was both six days after admission, and that was four days in the control group, with no significant difference (χ2=2.37, P=0.31). The median time for polymerase chain reaction (PCR) negative in the respiratory specimens in the three groups was all seven days after admission, and the PCR negative rates at day seven after admission in lopinavir/ritonavir, abidol and control groups were 71.8% (28/39), 82.6% (19/23) and 77.1% (27/35), respectively, which were not significantly different (χ2=0.46, P=0.79). Radiological worsening at day seven was observed in comparable proportions of patients in the three groups, which were 42.3% (22/52), 35.3% (12/34) and 52.1% (25/48), respectively(χ2=2.38, P=0.30). Adverse reactions occurred in 17.3% (9/52), 8.8% (3/34) and 8.3% (4/48) patients, respectively in the three groups (χ2=2.33, P=0.33). \n \n \nConclusions \nThis study does not find any effects of lopinavir/ritonavir and abidol on relieving symptoms or accelerating virus clearance. The efficacies of these two drugs in NCP treatment need further investigation. \n \n \nKey words: \nCoronavirus infections; Pneumonia; Validation studies; 2019 novel coronavirus; Lopinavir/ritonavir; Abidol","PeriodicalId":10127,"journal":{"name":"中华传染病杂志","volume":"38 1","pages":"86-89"},"PeriodicalIF":0.0000,"publicationDate":"2020-02-15","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"88","resultStr":"{\"title\":\"Efficacies of lopinavir/ritonavir and abidol in the treatment of novel coronavirus pneumonia\",\"authors\":\"Jun Chen, Y. Ling, X. Xi, Ping Liu, Feng Li, Tao Li, Zhiyin Shang, Mei Wang, Yinzhong Shen, Hongzhou Lu\",\"doi\":\"10.3760/CMA.J.ISSN.1000-6680.2020.02.006\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"Objective \\nTo evaluate the efficacies of lopinavir/ritonavir and abidol in the treatment of novel covonavirus pneumonia (NCP). \\n \\n \\nMethods \\nThe clinical data of 134 patients with NCP receiving treatment at Shanghai Public Health Clinical Center during January 20 to February 6, 2020 were retrospectively collected. All the patients received interferon-α2b spray and symptomatic supportive treatment, and 52 cases received oral lopinavir/ritonavir treatment, 34 cases received oral abidol treatment, the remaining 48 cases did not take any antiviral drugs. The efficacies of the three groups were compared, and Chi-square test was used for statistical analysis. \\n \\n \\nResults \\nThe 134 patients included 69 males (51.5%) and 65 females (48.5%), aged 35 to 62 years with the average of 48 years. The median time to temperature normalization in patients receiving abidol or lopinavir/ritonavir treatment was both six days after admission, and that was four days in the control group, with no significant difference (χ2=2.37, P=0.31). The median time for polymerase chain reaction (PCR) negative in the respiratory specimens in the three groups was all seven days after admission, and the PCR negative rates at day seven after admission in lopinavir/ritonavir, abidol and control groups were 71.8% (28/39), 82.6% (19/23) and 77.1% (27/35), respectively, which were not significantly different (χ2=0.46, P=0.79). Radiological worsening at day seven was observed in comparable proportions of patients in the three groups, which were 42.3% (22/52), 35.3% (12/34) and 52.1% (25/48), respectively(χ2=2.38, P=0.30). Adverse reactions occurred in 17.3% (9/52), 8.8% (3/34) and 8.3% (4/48) patients, respectively in the three groups (χ2=2.33, P=0.33). \\n \\n \\nConclusions \\nThis study does not find any effects of lopinavir/ritonavir and abidol on relieving symptoms or accelerating virus clearance. The efficacies of these two drugs in NCP treatment need further investigation. \\n \\n \\nKey words: \\nCoronavirus infections; Pneumonia; Validation studies; 2019 novel coronavirus; Lopinavir/ritonavir; Abidol\",\"PeriodicalId\":10127,\"journal\":{\"name\":\"中华传染病杂志\",\"volume\":\"38 1\",\"pages\":\"86-89\"},\"PeriodicalIF\":0.0000,\"publicationDate\":\"2020-02-15\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"\",\"citationCount\":\"88\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"中华传染病杂志\",\"FirstCategoryId\":\"3\",\"ListUrlMain\":\"https://doi.org/10.3760/CMA.J.ISSN.1000-6680.2020.02.006\",\"RegionNum\":0,\"RegionCategory\":null,\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"\",\"JCRName\":\"\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"中华传染病杂志","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.3760/CMA.J.ISSN.1000-6680.2020.02.006","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"","JCRName":"","Score":null,"Total":0}

引用次数: 88

摘要

目的评价洛匹那韦/利托那韦和阿比多尔治疗新型冠状病毒肺炎的疗效。方法回顾性收集2020年1月20日至2月6日在上海市公共卫生临床中心接受治疗的134例新冠肺炎患者的临床资料。所有患者均接受干扰素-α2b喷雾和症状支持治疗，52例接受口服洛匹那韦/利托那韦治疗，34例接受口服阿比多尔治疗，其余48例未服用任何抗病毒药物。比较三组疗效，采用卡方检验进行统计学分析。结果134例患者中男性69例（51.5%），女性65例（48.5%），年龄35～62岁，平均48岁。接受阿比多尔或洛匹那韦/利托那韦治疗的患者体温正常化的中位时间均为入院后6天，对照组为4天，差异无统计学意义（χ2=2.37，P=0.31），洛匹那韦/利托那韦、阿比多尔和对照组入院后第7天的PCR阴性率分别为71.8%（28/39）、82.6%（19/23）和77.1%（27/35），差异无统计学意义（χ2=0.46，P=0.79），三组不良反应发生率分别为17.3%（9/52）、8.8%（3/34）和8.3%（4/48）（χ2=2.33，P=0.033）。这两种药物治疗新冠肺炎的疗效有待进一步研究。关键词：冠状病毒感染；肺炎；验证研究；2019新型冠状病毒；洛匹那韦/利托那韦；阿比多尔

本文章由计算机程序翻译，如有差异，请以英文原文为准。

查看原文本刊更多论文

Efficacies of lopinavir/ritonavir and abidol in the treatment of novel coronavirus pneumonia

Objective To evaluate the efficacies of lopinavir/ritonavir and abidol in the treatment of novel covonavirus pneumonia (NCP). Methods The clinical data of 134 patients with NCP receiving treatment at Shanghai Public Health Clinical Center during January 20 to February 6, 2020 were retrospectively collected. All the patients received interferon-α2b spray and symptomatic supportive treatment, and 52 cases received oral lopinavir/ritonavir treatment, 34 cases received oral abidol treatment, the remaining 48 cases did not take any antiviral drugs. The efficacies of the three groups were compared, and Chi-square test was used for statistical analysis. Results The 134 patients included 69 males (51.5%) and 65 females (48.5%), aged 35 to 62 years with the average of 48 years. The median time to temperature normalization in patients receiving abidol or lopinavir/ritonavir treatment was both six days after admission, and that was four days in the control group, with no significant difference (χ2=2.37, P=0.31). The median time for polymerase chain reaction (PCR) negative in the respiratory specimens in the three groups was all seven days after admission, and the PCR negative rates at day seven after admission in lopinavir/ritonavir, abidol and control groups were 71.8% (28/39), 82.6% (19/23) and 77.1% (27/35), respectively, which were not significantly different (χ2=0.46, P=0.79). Radiological worsening at day seven was observed in comparable proportions of patients in the three groups, which were 42.3% (22/52), 35.3% (12/34) and 52.1% (25/48), respectively(χ2=2.38, P=0.30). Adverse reactions occurred in 17.3% (9/52), 8.8% (3/34) and 8.3% (4/48) patients, respectively in the three groups (χ2=2.33, P=0.33). Conclusions This study does not find any effects of lopinavir/ritonavir and abidol on relieving symptoms or accelerating virus clearance. The efficacies of these two drugs in NCP treatment need further investigation. Key words: Coronavirus infections; Pneumonia; Validation studies; 2019 novel coronavirus; Lopinavir/ritonavir; Abidol

求助全文

通过发布文献求助，成功后即可免费获取论文全文。去求助

来源期刊

中华传染病杂志

自引率

0.00%

发文量

5280

期刊介绍： The Chinese Journal of Infectious Diseases was founded in February 1983. It is an academic journal on infectious diseases supervised by the China Association for Science and Technology, sponsored by the Chinese Medical Association, and hosted by the Shanghai Medical Association. The journal targets infectious disease physicians as its main readers, taking into account physicians of other interdisciplinary disciplines, and timely reports on leading scientific research results and clinical diagnosis and treatment experience in the field of infectious diseases, as well as basic theoretical research that has a guiding role in the clinical practice of infectious diseases and is closely integrated with the actual clinical practice of infectious diseases. Columns include reviews (including editor-in-chief reviews), expert lectures, consensus and guidelines (including interpretations), monographs, short monographs, academic debates, epidemic news, international dynamics, case reports, reviews, lectures, meeting minutes, etc.